Biogen Promotes James C. Mullen to President and Chief Operating Officer
January 6, 1999 01:20 PM
CAMBRIDGE, Mass., Jan. 6 /PRNewswire/ -- Biogen, Inc. (BGEN) today announced that James C. Mullen has been promoted to the position of President and Chief Operating Officer, effective immediately. Mr. Mullen will report to James L. Vincent, Chairman and Chief Executive Officer, and will be responsible for all the operating functions of the Company, including Sales and Marketing, International, Operations, Medical Research, Regulatory Affairs, Product Development and Quality, and Program Executives, who lead the Company's development programs.
(Photo: newscom.com )
Mr. Mullen, 40, joined Biogen as Director, Facilities and Engineering, in 1989 and was named Vice President, Operations, in 1992. Since 1996, Mr. Mullen has served as Vice President, International, and has had responsibility for building all Biogen operations outside North America.
During his 10-year tenure at Biogen, Mr. Mullen has been credited with significant accomplishments by the Company. As Vice President, Operations, Mr. Mullen laid the manufacturing and distribution groundwork to launch AVONEX(R) (Interferon beta-1a), Biogen's flagship product for relapsing forms of multiple sclerosis, and he successfully oversaw the creation of Biogen's manufacturing capability in both Cambridge and Research Triangle Park. As Vice President, International, Mr. Mullen was the key Biogen executive responsible for the successful registration and launch of AVONEX(R) throughout Europe. AVONEX(R) is now available in more than 30 countries worldwide, and Biogen is the first biopharmaceutical company to launch one product on two continents concurrently. Mr. Mullen is credited with creating Biogen's direct sales organization in Europe, the largest in the biotechnology industry.
Jim Vincent, Biogen's Chairman and Chief Executive Officer, said, "Jim Mullen brings outstanding experience to this new senior management position. In his assignments as Vice President, Operations, and Vice President, International, Jim has consistently demonstrated the ability to lead large and diverse organizations and to manage through complex situations. He represents the leadership profile that has made Biogen what it is today."
From 1980 to 1989, Mr. Mullen held a variety of manufacturing and engineering positions at SmithKline-Beckman, including Director of Engineering. He holds a B.S. in Chemical Engineering from Rensselaer Polytechnic Institute and a M.B.A. from Villanova University.
Biogen, Inc., winner of the 1998 U.S. National Medal of Technology, is a biopharmaceutical company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. Headquartered in Cambridge, MA, the Company's revenues are generated from U.S. and European sales of AVONEX(R) (Interferon beta-1a) for treatment of relapsing forms of multiple sclerosis, and from the worldwide sales by licensees of a number of products, including alpha interferon and hepatitis B vaccines and diagnostic products. Biogen's research and development activities are focused on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases and in developmental biology and gene therapy. For copies of press releases and additional information about the Company, please consult Biogen's Homepage on the World Wide Web at biogen.com.
|
